Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics Inc. (MYGN) is a leader in molecular diagnostics and precision medicine, developing genetic tests that inform critical healthcare decisions across oncology, hereditary cancer risk assessment, and reproductive health. This news hub provides investors and healthcare professionals with timely updates on the company's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases and third-party analysis covering MYGN's financial results, product innovations, and clinical collaborations. Our curated collection includes updates on diagnostic test approvals, partnership announcements with healthcare systems, and developments in personalized treatment solutions. All content is organized chronologically for efficient tracking of the company's progress in genetic testing technologies.
Key areas of focus include updates to Myriad's hereditary cancer screening panels, advancements in tumor profiling accuracy, and expansions in pharmacogenomic testing capabilities. The page also tracks regulatory submissions and peer-reviewed study publications validating the company's diagnostic approaches.
Bookmark this page for streamlined access to Myriad Genetics' latest developments in DNA-based health solutions. Check regularly for updates on how MYGN continues shaping precision medicine landscape through innovative diagnostic technologies and evidence-based clinical tools.
Myriad Genetics (NASDAQ: MYGN) has finalized a $150 million cash deal to sell select assets and intellectual property, including the Vectra® test, to Labcorp. The transaction aims to enhance patient access to the Vectra test while allowing Myriad to focus on core areas like Women's Health, Oncology, and Mental Health. The Vectra test has been vital for over one million patients in assessing rheumatoid arthritis. Pending regulatory approval, the sale is expected to close by Q3 2021, with Guggenheim Securities as financial advisor.
Myriad Genetics announced its strategic updates during the 2021 Investor Day, focusing on expanding its reach in genetic testing and precision medicine. The company aims to increase growth while controlling expenses and enhancing operational excellence. This ongoing transformation includes new tech-enabled capabilities, better customer engagement, and plans for future growth. Myriad targets profitability by Q4 2021, emphasizing investments in product accessibility and leveraging genetic data for advancing healthcare services.
Myriad Genetics, Inc. (NASDAQ: MYGN) will release its financial results for the quarter ending March 31, 2021, on May 3, 2021, at 4:05 pm EDT. The company will not conduct a quarterly earnings call but will hold an Investor Day event on May 4, 2021, at 11:00 am EDT. This event will provide insights into the company's vision and future plans. Myriad is dedicated to advancing genetic testing and precision medicine to enhance patient care and reduce healthcare costs.
Myriad Genetics (NASDAQ: MYGN) has agreed to sell its myPath Melanoma laboratory to Castle Biosciences for $32.5 million. This strategic divestiture is aimed at enhancing shareholder value while allowing Myriad to concentrate on its core areas in Women's Health, Oncology, and Mental Health.
The myPath Melanoma test has served nearly 40,000 patients and is ordered by about 20% of dermatopathologists in the U.S. The deal is pending customary closing conditions and is expected to finalize in Myriad's fiscal second quarter.
Myriad Genetics (NASDAQ: MYGN) has formed a strategic collaboration with Intermountain Precision Genomics to enhance global precision oncology care. This venture integrates Myriad’s advanced genetic testing capabilities with Intermountain's laboratory services, launching a comprehensive offering of germline genetic testing and somatic tumor profiling expected to be available in late 2021. The collaboration includes Myriad's myRisk® and myChoice® CDx tests, supported by major insurance payers, aiming to provide complete genetic analysis for oncologists.
Myriad Genetics (MYGN) reported a 6% sequential revenue increase to $154.6 million for the quarter ending December 31, 2020, despite a 21% year-over-year decline. Test volumes rose 7% sequentially to 224,000, with adjusted EPS improving to ($0.12). The company signed an in-network agreement with Anthem Blue Cross Blue Shield, enhancing access for genetic tests. The business transformation plan includes focusing on women’s health, oncology, and mental health, while divesting less strategic units. Myriad did not provide financial guidance due to COVID-19 uncertainties.
Myriad Genetics (MYGN) announced new technology and healthcare leaders joining the company to drive transformation and growth. Key promotions include Kevin R. Haas as Chief Technology Officer and Faith Zaslavsky as President of Myriad Oncology. New executives include Maggie Ancona, David Hammer, Chris Williamson, Edward Gala, Karen Renner, Jackie Zou, and Justin Hunter. The company aims to enhance its operational excellence and strategic initiatives. Myriad was also recognized as a top workplace in the health industry, ranking first in cultural excellence and innovation.
Myriad Genetics (NASDAQ: MYGN) announced its upcoming quarterly earnings call for the period ending December 30, 2020, scheduled for 4:30 p.m. EST on February 23, 2021. The call will include insights from Paul J. Diaz, President and CEO, and R. Bryan Riggsbee, CFO, regarding the company's financial performance and business developments. Investors can participate via dial-in or live webcast. Following the call, an archived replay will be available for seven days.
Myriad Genetics has announced additional data from a study validating the effectiveness of its Prolaris test in determining treatment paths for men with prostate cancer. The study, presented at the ASCO-GU symposium, indicates Prolaris can identify patients who require intensive therapy versus those who can be monitored. With an estimated 248,530 prostate cancer cases expected in the U.S. this year, the test helps avoid overtreatment. Approximately 60% of men with prostate cancer have insurance coverage for Prolaris, reflecting the company's commitment to expanding access.
Myriad Genetics, a leader in genetic testing, will participate in key health and technology conferences in February and March 2021. Executives Paul J. Diaz and R. Bryan Riggsbee will host fireside chats at the BTIG Virtual Conference on February 19, the Leerink Global Healthcare Conference on February 24, and the Cowen Annual Healthcare Conference on March 2. These discussions will focus on enhancing services in Women's Health, Oncology, and Mental Health. Live audio webcasts will be available on Myriad's website.
FAQ
What is the current stock price of Myriad Genetics (MYGN)?
What is the market cap of Myriad Genetics (MYGN)?
